Bendamustine Hydrochloride Accord 2.5 Mg/ Ml Powder For Concentrate For Solution For Infusion
Chronic lymphocytic leukaemia
Bendamustine hydrochloride 100 mg per square metre of your body surface area (based on your height and weight)
on Days 1+2
Repeat the cycle after 4 weeks up to 6 times
Bendamustine hydrochloride 120 mg per square metre of your body surface area (based on your height and weight)
on Days 1 + 2
Repeat the cycle after 3 weeks at least 6 times
Bendamustine hydrochloride 120-150 mg per square metre of your body surface area (based on your height and weight)
on Days 1 + 2
Prednisone 60 mg per square metre of your body surface area (based on your height and weight) i.v. or per os.
on Days 1 - 4
Repeat the cycle after 4 weeks at least 3 times
The name of your medicine is Bendamustine hydrochloride 2.5 mg/ml powder for concentrate for solution for infusion' but in the rest of the leaflet it will be called “Bendamustine hydrochloride”.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist or healthcare professional. This includes any possible side effects not listed in this leaflet. See section 4.
1. What Bendamustine hydrochloride is and what it is used for
2. What you need to know before you use Bendamustine hydrochloride
3. How to use Bendamustine hydrochloride
4. Possible side effects
5. How to store Bendamustine hydrochloride
6. Contents of the pack and other information
Bendamustine hydrochloride is a medicine which is used for the treatment of certain types of cancer (cytotoxic medicine).
Bendamustine hydrochloride is used alone (monotherapy) or in combination with other medicines for the treatment of the following forms of cancer:
- chronic lymphocytic leukaemia in cases where fludarabine combination chemotherapy is not appropriate for you,
- non-Hodgkin lymphomas, which had not, or only shortly, responded to prior rituximab treatment,
- multiple myeloma in cases where high-dose chemotherapy with autologous stem cell transplantation, thalidomide or bortezomib containing therapy is not appropriate for you.
Do not use Bendamustine hydrochloride:
- if you are hypersensitive (allergic) to the active substance bendamustine hydrochloride or any of the other ingredients of this medicine (listed in section 6);
- while breast-feeding;
- if you have severe liver dysfunction (damage to the functional cells of the liver);
- if you have yellowing of the skin or whites of the eyes caused by liver or blood problems (jaundice);
- if you have severely disturbed bone marrow function (bone marrow depression) and serious changes in your number of white blood cells and platelets in the blood (white blood cells and/or thrombocyte values drop to < 3,000/pl or < 75,000/pl, respectively.);
- if you have had major surgical operations less than 30 days before starting treatment;
- if you have an infection, especially one accompanied by a reduction in white blood cells (leucocytopenia);
- in combination with yellow fever vaccines.
Talk to your doctor before using Bendamustine
- in case of reduced capability of the bone marrow to replace blood cells. You should have your number of white blood cells and platelets in the blood checked before starting treatment with Bendamustine hydrochloride, before each subsequent course of treatment and in the intervals between courses of treatment.
- in case of infections. You should contact your doctor if you have signs of infection, including fever or lung symptoms.
- in case of reactions on your skin during treatment with Bendamustine hydrochloride.
The reactions may increase in severity.
- in cases of existing heart disease (e.g. heart attack, chest pain, severely disturbed heart rhythms).
- in case you notice any pain in your side, blood in your urine or reduced amount of urine. When your disease is very severe, your body may not be able to clear all the waste products from the dying cancer cells. This is called tumour lysis syndrome and can cause kidney failure and heart problems within 48 hours of the first dose of Bendamustine hydrochloride. Your doctor will be aware of this and may give you other medicines to help prevent it.
- in case of severe allergic or hypersensitivity reactions. You should pay attention to infusion reactions after your first cycle of therapy.
Men receiving treatment with Bendamustine hydrochloride are advised not to conceive a child during treatment and for up to 6 months afterwards. Before starting treatment, you should seek advice on storing sperm because of the possibility of permanent infertility.
Unintentional injection into the tissue outside blood vessels (extravasal injection) should be stopped immediately. The needle should be removed after a short aspiration. Thereafter the affected area of tissue should be cooled. The arm should be elevated. Additional treatments like the use of corticosteroids are not of clear benefit (see section 4).
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
If Bendamustine hydrochloride is used in combination with medicines which inhibit the formation of blood in the bone marrow, the effect on the bone marrow may be intensified.
If Bendamustine hydrochloride is used in combination with medicines which alter you immune response, this effect may be intensified.
Cytostatic medicines may diminish the effectiveness of live-virus vaccination. Additionally cytostatic medicines increase the risk of an infection after vaccination with live vaccines (e.g. viral vaccination).
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Bendamustine hydrochloride can cause genetic damage and has caused malformations in animal studies. You should not use Bendamustine hydrochloride during pregnancy unless certainly indicated by your doctor. In case of treatment you should use medical consultation about the risk of potential adverse effects of your therapy for the unborn child and genetic consultation is recommended.
If you are a woman of childbearing potential you must use an effective method of contraception both before and during treatment with Bendamustine hydrochloride. If pregnancy occurs during your treatment with Bendamustine hydrochloride you must immediately inform your doctor and should use genetic consultation.
If you are a man, you should avoid fathering a child during treatment with Bendamustine hydrochloride and for up to 6 months after treatment has stopped. There is a risk that treatment with Bendamustine hydrochloride will lead to infertility and you may wish to seek advice on conservation of sperm before treatment starts.
Bendamustine hydrochloride must not be administered during breast-feeding. If treatment with Bendamustine hydrochloride is necessary during lactation you must discontinue breast-feeding.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
No studies on the effects on the ability to drive and to use machines have been performed. Do not drive or operate machines if you experience side effects, such as dizziness or lack of coordination.
Bendamustine hydrochloride is administered into a vein over 30-60 minutes in various dosages, either alone (monotherapy) or in combination with other medicines.
Treatment should not be started if your white blood cells (leukocytes) have fallen to counts below 3,000 cells/pl and/or your blood platelets have fallen to counts below 75,000 cells/pl.
Your doctor will determine these values at regular intervals.
Treatment should be terminated if white blood cell (leukocyte) and/or platelet values dropped to < 3,000/pl or < 75,000/pl, respectively. Treatment can be continued after white blood cell values have increased to > 4,000/pl and platelet values to > 100,000/pl.
Impaired liver or kidney function Dependent on the degree of impairment of your liver function it may be necessary to adjust your dose (by 30% in case of moderate liver dysfunction). No dose adjustment is necessary in case of impairment of kidney function. Your attending doctor will decide whether a dosage adjustment is necessary.
How it is administered
Treatment with Bendamustine hydrochloride should be undertaken only by doctors experienced in tumour therapy. Your doctor will give you the exact dose of Bendamustine hydrochloride and use the necessary precautions.
Your attending doctor will administer the solution for infusion after preparation as prescribed. The solution is administered into a vein as a short-term infusion over 30 - 60 minutes.
Duration of use
There is no time limit laid down as a general rule for treatment with Bendamustine hydrochloride. Duration of treatment depends on disease and response to treatment.
If you are at all worried or have any questions regarding treatment with Bendamustine hydrochloride, please speak to your doctor or pharmacist.
If a dose of Bendamustine hydrochloride has been forgotten, your doctor will usually retain the normal dosage schedule.
The doctor treating you will decide whether to interrupt the treatment or to change over to a different preparation.
As with all similar cytotoxic substances, stricter safety precautions apply as far as nursing staff and doctors are concerned, due to the potentially genome-damaging and cancer-causing effect of the preparation. Avoid inhalation (breathing in) and contact with the skin and mucous membranes when handling Bendamustine hydrochloride (wear gloves, protective clothing, and possibly a face mask!). If any parts of the body become contaminated, clean them carefully with soap and water, and flush the eyes with
0.9% (isotonic) saline solution. If possible, it is advisable to work on a special safety work bench (laminar flow) with a disposable absorbent sheet that is impermeable to liquids. Contaminated articles are cytostatic waste. Please comply with national guidelines on the disposal of cytostatic material. Pregnant staff must be excluded from working with cytostatics.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Bendamustine hydrochloride can cause side-effects, although not everybody gets them.
Tissue changes (necrosis) have been observed very rarely following unintentional injection into the tissue outside blood vessels (extravascular).
A burning sensation where the infusion needle is inserted may be a sign for administration outside the blood vessels.
The consequence of administration in this way can be pain and poorly healing skin defects.
The dose-limiting side-effect of Bendamustine hydrochloride is impaired bone-marrow function, which usually returns to normal after treatment. Suppressed bone marrow function increases the risk of infection.
• Low counts of white blood cells (leukocytopenia)
• Decrease in the red pigment of the blood (haemoglobin)
• Low counts of platelets (thrombocytopenia)
• Feeling sick (nausea)
• Mucosal inflammation
• Increased blood level of creatinine
• Increased blood level of urea
• Bleeding (haemorrhage)
• Disturbed metabolism caused by dying cancer cells releasing their contents into the blood stream
• Reduction in red blood cells which can make the skin pale and cause weakness or breathlessness (anaemia)
• Low counts of neutrophils (neutropenia)
• Hypersensitivity reactions such as allergic inflammation of the skin (dermatitis), nettle rash (urticaria)
• A rise in liver enzymes AST/ALT
• A rise in the enzyme alkaline phosphatase
• A rise in bile pigment
• Low potassium blood levels
• Disturbed function (dysfunction) of the heart
• Disturbed heart rhythms (arrhythmia)
• Low or high blood pressure (hypotension or hypertension)
• Disturbed lung function
• Sore mouth (Stomatitis)
• Loss of appetite
• Hair loss
• Skin changes
• Missed periods (amenorrhoea)
Do not use Bendamustine hydrochloride after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month.
This medicinal product does not require any special temperature storage conditions. Keep the container in the outer carton to protect the content from light.
Solutions for infusions prepared according to the directions listed at the end of this leaflet are stable in polyethylene bags at 25°C for 3.5 hours, and at 2°C to 8°C they are stable for 2 days.
Bendamustine hydrochloride contains no preservatives. From a microbiological point of view, the solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. It is the responsibility of the user to maintain aseptic conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substance is bendamustine hydrochloride. One vial contains 25 mg of bendamustine hydrochloride (as bendamustine hydrochloride monohydrate).
One vial contains 100 mg of bendamustine hydrochloride (as bendamustine hydrochloride monohydrate).
After reconstitution 1 ml of the concentrate contains 2.5 mg bendamustine hydrochloride (as bendamustine hydrochloride monohydrate).
The other ingredient is mannitol.
Amber glass vials with bromobutyl rubber stopper and an aluminium flip-off cap.
Bendamustine hydrochloride is available in packs containing 5, 10 and 20 vials with 25 mg of bendamustine hydrochloride and 1 and 5 vials with 100 mg of bendamustine hydrochloride.
Not all pack sizes may be marketed.
Accord Healthcare Limited
Sage House, 319 Pinner Road, North Harrow,
Middlesex HA1 4HF, United Kingdom.
Accord Healthcare Limited
Sage House, 319 Pinner Road, North Harrow,
Middlesex HA1 4HF, United Kingdom.
Wessling Hungary Kft
Foti ut 56 , Budapest 1047 Hungary
• Accumulation of fluid in the heart sac (escape of fluid into the pericardial space)
• Infection of the blood (sepsis)
• Severe allergic hypersensitivity reactions (anaphylactic reactions)
• Signs similar to anaphylactic reactions (anaphylactoid reactions)
• Loss of voice (aphonia)
• Acute circulatory collapse
• Reddening of the skin (erythema)
• Inflammation of the skin (dermatitis)
• Itching (pruritus)
• Skin rash (macular exanthema)
• Excessive sweating (hyperhidrosis)
• Primary atypical inflammation of the lungs (pneumonia)
• Break-down of red blood cells
• Rapid decrease in blood pressure sometimes with skin reactions or rash (anaphylactic shock)
• Disturbed sense of taste
• Altered sensations (paraesthesia)
• Malaise and pain in the limbs (peripheral neuropathy)
• Disease of the nervous system (anticholinergic syndrome)
• Neurological disorders
• Lack of coordination (ataxia)
• Inflammation of the brain (encephalitis)
• Increased heart rate (tachycardia)
• Heart attack, chest pain (myocardial infarct)
• Heart failure
• Inflammation of the veins (phlebitis)
• Formation of tissue in the lungs (fibrosis of the lungs)
• Bleeding inflammation of the gullet (haemorrhagic oesophagitis)
• Bleeding of stomach or gut
• Multiple organ failure
There have been reports of secondary tumours (myelodysplastic syndrome, acute myeloid leukemia (aMl), bronchial carcinoma) following treatment with Bendamustine hydrochloride. No clear relationship with Bendamustine hydrochloride could be determined.
A small number of cases of severe skin reactions (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis) have been reported.
The relationship with Bendamustine hydrochloride is unclear.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system (see contact details below).
By reporting side effects you can help provide more information on the safety of this medicine
Yellow Card Scheme
This medicinal product is authorised in the Member States of the EEA under the following names:
Name of the medicinal product
Bendamustine Accord 2.5 mg/ml Pulver fur ein Konzentrat zur Herstellung einer Infusionslosung Bendamustinhydrochlorid Accord Bendamustine Accord 2.5 mg/ml kuiva-aine valikonsentraatiksi infuusionestetta varten, liuos Bendamustine 25 mg/100mg Powder for concentrate for Solution for Infusion Bendamustine Accord 2,5 mg/ml stofn fyrir innrennslis^ykkni, lausn Bendamustine Accord Bendamustine Accord Bendamustina Accord 2.5 mg/ml polvo para concentrado para solucion para perfusion Bendamustine Accord 2,5 mg/ml prasok na infuzny koncentrat Bendamustine Accord 2,5 mg/ml Pulver fur ein Konzentrat zur Herstellung einer Infusionslosung Bendamustine Accord 2,5 mg/ml npax 3a KOHiqeHTpaT 3a HH$y3HOHeH pa3TBop Bendamustine Accord 2.5 mg/ml Bendamustine Accord 2,5 mg/ml prasek pro koncentrat pro infuznl roztok
Bendamustine Accord 2,5 mg/ml Pulver zur Herstellung eines Infusionslosungskonzentrats Bendamustine Accord Bendamustine Accord 2.5 mg/ml powder for concentrated solution for infusion
Bendamustine Accord 2,5mg/ml por oldatos infuziohoz valo koncentratumhoz Bendamustina Accord Bendamustine Accord 2.5 mg/ml pulveris infuziju skTduma koncentrata pagatavosanai Bendamustine Accord 2.5 mg/ml milteliai koncentratui infuziniam tirpalui
2.5 mg/ml powder for concentrate for solution for infusion
The Netherlands Bendamustine Accord 2,5 mg/ml poeder voor concentraat voor oplossing voor infusie Bendamustine Accord 2,5 mg/ml po para concentrado para solugao para perfusao Bendamustina Accord 2,5 mg/ ml pulbere pentru concentrat pentru solutie perfuzabila Bendamustine Accord 2,5 mg/ ml prasek za koncentrat za raztopino za infundiranje
Bendamustine Accord 2,5 mg/ ml pulver till koncentrat till infusions vatska, losning
2.5 mg/ ml Powder for concentrate for solution for infusion BENDAMUSTINE ACCORD
2.5 mg/ml, poudre pour solution a diluer pour perfusion
Name of the Member State Austria
Slovak Republic Belgium
Keep this medicine out of the sight and reach of children.
The solution ready for use must be prepared by dissolving the contents of a vial of Bendamustine hydrochloride exclusively in water for Injections, as follows:
1. Preparation of the concentrate
• One vial of Bendamustine hydrochloride containing 25 mg of bendamustine hydrochloride is first dissolved in 10 ml by shaking
• One vial of Bendamustine hydrochloride containing 100 mg of bendamustine hydrochloride is first dissolved in 40 ml by shaking
2. Preparation of the solution for infusion As soon as a clear solution is obtained (generally after 5 - 10 minutes), the total recommended dose of Bendamustine hydrochloride is immediately diluted with 0.9% (isotonic) saline solution to obtain a final volume of approximately 500 ml. Bendamustine hydrochloride must not be diluted with other solutions for infusion or injection. Bendamustine hydrochloride must not be mixed in an infusion with other substances.